$TRVN Regarding approval timing, the QTi data is much more extensive than previous "thorough QT study designs" so the data won't be in the same format as the original filing. As a result, Carrie indicated on their CC they: "expect that we'd have a Class II review, which is 6 months, and then we'll have a DEA scheduling on the back end of that, so another 3 months. So the expectation is that we would potentially have an approval the 2nd half of next year." Adjust your expectations accordingly, but keep in mind this stock should be a 5+ bagger by this time next year. I'm will to hold and wait a while for those kind of returns.